First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Surgical treatment of chronic pancreatitis is challenging in children and especially laparoscopic surgery has been rarely reported, worldwide
Multiples is the first private equity (PE) investor in the company
The new hospital is expected to open by March'24
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The plan is to advance innovative therapies to drug-resistant cancers
Subscribe To Our Newsletter & Stay Updated
